HA- SANPs were also obtained with HA-VES and proposed as nanocarriers for DOX treatment in Adriamycin resistant breast cancer cells [182], as well as for the combined DOX/CUR [183] or DTX/programmed cell death ligand 1 (PD-L1) antibodies (anti-PD-L1) [184] protocols exploiting CUR as coadjuvant and the Anti-PD-L1 as an immune checkpoint. Here, CD274 is linked to breast carcinoma.